ie. chronic skin inflammation with joint inflammation psoriasis and psoriatic arthritis
Conditions
Interventions
None listed
Sponsors
Maasstadziekenhuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria psoriasis patients: - patients that are diagnosed with psoriasis by their dermatologist - age * 18 years - written informed consent by the patient;Inclusion criteria psoriatic arthritis patients: - Psoriasis patients that are diagnosed with psoriatic arthritis by their rheumatologist (according to the CASPAR criteria) - age * 18 years - written informed consent by the patient;Inclusion criteria healthy volunteer: - age * 18 years - WHO performance score 0 - age and sex matched (for psoriasis and psoriatic arthritis) - written informed consent ;Inclusion criteria systemic sclerosis patients: - Patients that are diagnosed with systemic sclerosis by their rheumatologist - age * 18 years - written informed consent given by the patient;Inclusion criteria systemic lupus erythematodes patients: - Patients that are diagnosed with systemic lupus erythematodes by their rheumatologist - age * 18 years - written informed consent given by the patient;Inclusion criteria vasculitis patients with skin involvement: - Patients that are diagnosed with vasculitis by their rheumatologist - age * 18 years - written informed consent given by the patient;Human tissues;Inclusion criteria for tissue donors, ie. skin tissue: patients undergoing eyelid surgery; mammareduction/abdominoplasty; synovial tissue: knee-replacement therapy in PsA and osteoarthritis (orthopedic surgery), synovectomy wrist (plastic surgery) - donors will be asked for their permission to use their materials anonymously; this will be recorded in their medical file.;Inclusion criteria for tissue donors, ie. patients undergoing vascular surgery. The 3 categories of vascular surgery patients that will be included are patients undergoing crossectomy in chronic venous insufficiency; carotid endarterectomy, and surgical bypass of aortoiliac occlusive disease in patients with intermittent claudicatio without any signs of infection or critical (limb) ischemia. - written informed consent given by the patient
Exclusion criteria
Exclusion criteria: - use of corticosteroids including topical or systemic for the last 6 weeks - use of disease-modifying antirheumatic drugs (DMARDs) or immune-suppressive drugs for the last 6 weeks - concomitant use of drugs affecting the lymphatic system and/or immune responses including non-steroidal anti-inflammatory drugs (NSAIDs), drugs targeting RAAS system, and anti-allergy medication. These agents must be discontinued at least 6 weeks before the screening visit. - co-existence of chronic inflammatory disorders including eczema, asthma or chronic infection - pregnancy - active cancer - any lymphatic, cardiovascular or immunodeficiency disorder
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective 1. Study parameter: To establish that skin-derived and synovium-derived LECs in PsA drive the in vivo mechanisms that coordinate the programming of dermal pathogenic T-cells to adopt a synovial joint homing profile, ie. enhanced expression of CD161, CCR6, CCR7, CCR2, CXCR6, and loss of skin homing receptors such as CCR4, CCR10 and CLA(based on recent literature) Outcome Expected results In these experiments, we expect to find that dermal LECs from PsA patients (in contrast to PsO and controls) are capable of imprinting skin-derived T-cells with a synovial joint homing phenotype that promote their egress towards synovial joint compartments. | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective 2. To investigate whether the induction of tissue-imprinting receptors on allogenic skin-derived T-cells, as demonstrated in Aim 1, leads to enhanced T-cell migration into the afferent lymphatic vessels of a human dermal sheet (crawl-in assay). Outcome: Should an effect of PsA-induced inflammatory changes in LECs on the homing profile of these skin-derived T-cells be confirmed, this will most likely have a direct impact on the T-cell migratory response as reflected by an increased entry into afferent lymphatics in the crawl-in assay. Objective 3. To investigate whether overlapping properties may be present in LECs from the skin, synovial tissue and lymph nodes. | — |
Countries
Netherlands
Outcome results
None listed